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Abstract: Chronic kidney disease (CKD) patients are at an increased risk of cardiovascular complications and plasma
leptin level is elevated in cardio renal syndrome. We wanted to explore leptin levels in patients with different stages of
CKD and find its association with risk of cardiovascular disease. This cross-sectional study was conducted in
Nephrology Department of Jinnah Post Graduate Medical Centre (JPMC) from January 2014 to September 2014. Group
I comprised of controls (GFR=116±8.3, n = 44) acquired from general population, CKD patients were grouped as II, III
and IV respectively with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n=42) and 20.22±8.4 (n = 42).CKD patients with any
inflammatory disease, Diabetes Mellitus and on steroid therapy were excluded. Serum leptin, lipid profile and C reactive
proteins (CRP) were measured. Leptin and CRP levels increased significantly with progression of CKD. High density
lipoproteins (HDL) to low density lipoproteins (LDL) ratio was significantly high in control as compared to CKD groups
(p<0.001). A positive correlation of leptin was observed with CRP and HDL/LDL ratio (r= 0.994,p<0.001 and r=
-0.403p<0.001) respectively. Hyperleptinemia observed with progression of CKD contributed to pathogenesis of
cardiovascular disease by decreasing HDL/LDL ratio.
Keywords: Chronic Kidney disease, C reactive protein, Leptin, HDL/LDL ratio

INTRODUCTION
End-stage renal disease (ESRD) is a complication of
impaired renal function and chronic kidney disease
(CKD) associated with increased morbidity, mortality, and
increases the risk of cardiac disease (CVD).The
prevalence of CKD is high in Pakistani population, since
incidence of hypertension and diabetes in our inhabitants
is one of the highest in the world.
CKD is linked to a series of multiple toxic physiological
and metabolic functions. Diabetes and hypertension as
being its complication are concomitant with lethal
outcomes. An increased risk of CVD in these patients can
lead to mortality(Locatelli et al., 2003) which is attributed
to inflammatory and oxidative stress, erythropoietin(EPO)
resistance leading to anemia(Kazory and Ross 2009),
vitamin D deficiency (Levin and Li 2005) and vascular
calcification (Mizobuchi et al., 2009). Adipocytokines
such as leptin, are also potentially involved in the
pathogenesis of metabolic syndrome (e.g. dyslipidemia)
in End-stage renal disease (Mak and Cheung 2007).
Leptin is an adipose tissue-derived hormone that has been
associated to numerous metabolic and inflammatory
factors involved in the pathogenesis of hypertension and
cardiovascular disease (Wannamethee et al., 2007).
Increased leptin levels are in response to high energy
deposition in the form of adipocytes and obesity,
irrespective of the degree of BMI (Fatima et al., 2013).In
renal disease the scenario is much different, as the
initially CKD may be altered with change in grades of
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obesity; and therefore increasing leptin levels and
resistance (fig. 1). Hyperleptinemia is observed in patients
during CKD progression and potentially anorexiccachectic syndrome. However, histological changes in the
basement membrane from initial to end stage disease may
also contribute to the decreased levels of leptin at the end
stage of CKD (Becker et al., 2005). Leptin is known to be
important in the regulation of food desire, body
composition and might also be responsible for metabolic
changes during CKD leading to inflammation and loss of
lean body mass (Mak et al., 2006).

[SF1]

Fig. 1: This diagram shows the illustration of the
hypothetical mechanism of etiology of Chronic Kidney
Disease.
The etiology of kidney dysfunction may initially be
associated with long-standing obesity and insulin
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resistance, like the metabolic syndrome (MetS). Leptin is
predominantly washed out from the circulation by the
kidneys after the metabolic degradation in the renal
tubules (Cumin et al., 1996). Shamsuzzaman et al.
(Shamsuzzaman et al., 2004) established an association
between serum levels of leptin and C-reactive protein
(CRP) in healthy young adults. Leptin plays a role in
stimulating the sympathetic system of the body leading to
elevated blood pressure and deranged GFR(Carlyle et al.,
2002 including natriuresis (Jackson and Li 1997)to
maintain the electrolyte homeostasis (Hall et al., 1990).
The reduced clearance of plasma leptin leads to high
levels of circulating leptin probably due to feedback-loop
that down regulates certain genes in hyperleptinemic
patients having advanced CKD (Nordfors et al., 1998).
Increased adiposity (measured in reference to BMI) is
associated with increased serum leptin levels as it is
recognized to proportional to obesity. The oxidative stress
caused by the activation of reactive oxygen specie (ROS)
during the sub clinical inflammatory condition during
obesity, leads to the damage of the podocytes thus leading
to advanced CKD (Sharma et al., 2008).
The objective of the study was to explore leptin levels in
patients with different stages of ESRD and find its
association with metabolic dysfunction in CKD patients.
With the agreement that obesity and hyperleptinemia both
cause metabolic dysfunction in CKD patients, we selected
patients with normal BMI and then studied the
relationship of Leptin, inflammatory marker reactive
protein and metabolic dysfunction in CKD patients.

MATERIALS AND METHODS
Study participants
This cross-sectional study was conducted in the
Department of Biological and Biomedical Sciences
(BBS), Aga Khan University in collaboration with the
Nephrology Department of J.P.M.C. during the period of
January 2014 to September 2014. Two hundred patients
were recruited for the study out of which 170 subjects
were enrolled in present study. CKD patients between the
ages 35- 45 years without any known cardiovascular
disease were recruited. We excluded the patients with
Diabetes Mellitus, liver disease, acute or chronic
inflammatory disease and patient on steroid therapy. Total
of 170 were divided into four groups as: Group I control
subjects (GFR=116±8.3, n = 44), recruited from BBS,
Aga Khan University. Group II, III and IV were CKD
patients with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n =
42) and 20.22±8.4 (n = 42), respectively were enrolled
from Nephrology department of JPMC.
Ethics statement
The research protocol was approved by the Institutional
Review Board of the Basic Medical Science Institute,
Jinnah
Postgraduate
Medical
Centre
(NO.F.1-
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2/2013/BMSI-E.COMT/003/ JPMC). Written informed
consents were attained from study subjects and all
investigations were conducted in accordance with the
principles expressed in the Declaration of Helsinki.
Consent for the publication of the clinical details was also
obtained.
Data collection
At the time of enrollment questionnaire was employed to
record the baseline demographic and clinical data of the
study subjects from their medical records. All study
participants were requested to come with 10-12 hours
overnight fasting for sample collection. The analysis of
biochemical
parameters
including
Cholesterol,
Triglycerides and HDL-c were measured by
spectrophotometry using commercially available Merck
kits. Low density lipoprotein (LDL-c) was measure by
Friedwal’s formula (Friedewald et al., 1972). CRP
(mg/dl) were determined by Enzyme Linked ImmunoSorbent Assay kit method Glomerular filtration rate
(GFR) was estimated by Cockcroft & Gault
equation(Cockcroft and Gault 1976). Serum leptin levels
were measured by commercially available ELISA kits
method. Serum HDL-cholesterol was determined by kit
manufactured by Merck, France. LDL-cholesterol was
calculated according to Friedewald’s formula (Friedewald
et al., 1972). Triglycerides were determined by using
Glycerol-3-Phosphate Oxidase Phenol Aminophenanzone
(GPO-PAP) method, by Merck, France. Serum cholesterol
was estimated by enzymatic colorimetric (CHOD-PAP)
method, manufactured by Merck, France (Rifai and
Warnick 2006)

STATISTICAL ANALYSIS
In this study SPSS (version 11; SPSS Inc., Chicago, IL,
USA) was used to statistically analyze the descriptive data
of continuous variables including age, height, weight,
BMI and blood pressure along with serum Cholesterol,
Triglycerides, HDL-C and LDL-c mean ± standard
deviation (SD). Statistical comparisons were calculated
using a student t-test and Mann Whitney U test for
continuous/quantitative variables. Pearson’s coefficient of
correlation (r) was used for the determination of the
correlation of GFR levels with and lipid profile. In all
statistical analysis performed p-values <0.05 were
considered significant.

RESULTS
Total of 170 subjects had mean BMI of 22.32±0.9
Kg/m2and mean leptin levels 8.26±4.6 ng/ml. Leptin
levels increased significantly with progression of
CKD.CRP was significantly increased in CDK groups as
compared to group I (table 1). In lipid profile, cholesterol,
triglyceride and LDL were significantly high in CKD
groups (p<0.001), while HDL was significantly low
Pak. J. Pharm. Sci., Vol.----, No.0, ---------- 20----, pp.000-000
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Table 1: Comparison of biophysical and biochemical Parameters among all groups

Variable
Age (year)
Weight (kg)
Leptin (ng/ml)
CRP (mg/dl)
Cholesterol (mg/dl)
Triglycerides (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
HDL/LDL ratio

Group I
(control,
n= 44)
Mean ± SD
55.73 ± 2.47
58.7 ± 2.47
2.56±1.3
2.80±0.84
147.4±12.28
118.5±11.66
41.14±11.86
80.21±13.98
0.7054±0.08

Group II
(CKD Stage II,
n = 42)
Mean ± SD
54.78±2.54
62.9±9.7
6.58±1.94*
3.2±0.12
176±5.84
122±9.56
34.85±6.25
101.5±16.52
0.5779±0.08

Group III
(CKD Stage III,
n = 42)
Mean ± SD
55.42±3.42
68.311±9.54
10.21±1.9°*
3.75±0.56
198±9.24
169±8.65
36.12±5.94
145±19.23
0.46±0.10

Group IV
(CKD Stage IV,
n = 42)
Mean ± SD
57.56 ±5.49
64.9 ± 9.7
13.45±3.05ꜝ
4.00 ±0.76*
229.86±17.65*
186.7±9.19ꜝ
30.43±13.5*
161.1±12.95ꜝ
0.25±0.03

p value
>0.5
<0.5
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

*significant as compared to controls, p<0.01,°significant as compared to group II, p<0.01, #significant as compared to controls and
overweight p<0.01,ꜝsignificant as compared to group I, II, III p<0.01

(p<0.001), as compared to Group I (table 1). The
HDL/LDL ratio was significantly reduced with
progression of CKD. A positive correlation was observed
between leptin and CRP as shown in fig. 2 (r=0.994,
p<0.001).Correlation of Leptin with HDL/LDL ratio
showed an inverse correlation r=-0.403 with p<0.001.

associated with increased atherosclerotic CVD risk (Kwan
et al., 2007, Thomas et al., 2008). Same pattern of uremic
lipid profile has been evident in our CKD population with
gradual shift towards altered cholesterol, triglyceride and
HDL. Various elements are concomitant with the
development of dyslipidemia in chronic renal impairment
(Kwan et al., 2007).
Inflammation probably plays a key role in the initiation
and progression of the atherosclerotic process(Ross
1999). High serum concentrations of systemic
inflammatory markers such as CRP have been associated
with atherosclerosis (Stenvinkel et al., 2008).
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Fig. 2: Correlation of Leptin and C-Reactive protein

DISCUSSION
There have been various studies exploring the serum
leptin levels in different conditions but none points out it’s
relation to metabolic dysfunction in CKD Pakistani
population. To fill this gap we designed this study to
assess the levels of leptin and CRP in CKD patients.
Generally, high plasma concentrations of cholesterol,
LDL, and to some extent high total triglyceride
concentrations with low concentrations of HDL, are
Pak. J. Pharm. Sci., Vol.----, No.0, ---------- 20----, pp.000-000

It has been observed that increased BMI of CKD patients
mediate link between obesity and CVD by its effects on
arterial pressure (Menendez et al., 2000), inflammatory
vascular response (Konstantinides et al., 2001, Bodary et
al., 2002), and platelet aggregation (Chaldakov et al.,
2001, Cooke and Oka 2002). Several studies advocate that
adipose tissue releases leptin (Friedman and Halaas 1998)
which possesses cytokine-like properties which is
responsible for elevated IL-6 and C reactive proteins. The
research of ours study highlight the role of Leptin in
patients of normal BMI. Our study is strengthened by
other studies in CKD patients where CRP was found to be
associated with renal disease explained by the reactive
oxygen specie being activated and causing an
inflammatory condition. This inflammation under such
conditions might cause altered lipid profile, thus increase
risk for cardiovascular involvement (Briffa et al., 2013).

CONCLUSION
Hyperleptinemia in progressive CKD patients of our
population demonstrated high CRP with low HDL/LDL
ratio. This association explains the relationship of raised
Leptin levels and CRP in progression of CKD as well as
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metabolic dysregulation that may lead to pathogenesis of
cardiovascular disease in advanced CKD patients.
Implication of the study
Future longitudinal studies are required to explicate the
possible mechanisms by which leptin causes metabolic
dys regulations in cardiovascular diseases.
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